Introduction {#Sec1}
============

About 15% of breast cancer over-expresses the human epidermal growth factor receptor 2 (HER2) \[[@CR1],[@CR2]\]. HER2 is a transmembrane tyrosine kinase receptor that is a member of the human epidermal growth factor receptor (EGFR/HER) family. This receptor is involved in proliferation and survival of epithelial cells. Activation of HER2 generates activation of downstream signaling pathways including mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K/Akt) \[[@CR3]\]. Over-expression of HER2 predicts poorer prognosis \[[@CR4],[@CR5]\] and higher sensitivity to chemotherapy, such as anthracycline and paclitaxel \[[@CR5],[@CR6]\]. On the opposite side, HER2 overexpression has been associated with resistance to tamoxifen \[[@CR6]--[@CR9]\]. Finally, HER2 positive breast cancer is associated with an increased risk of brain metastases \[[@CR10]\].

Trastuzumab is a humanized recombinant monoclonal antibody that targets the HER2 extracellular domain. The use of trastuzumab is considered as standard of care both in early and metastatic HER2 over-expressing breast cancer. Numerous clinical trials have confirmed that trastuzumab improves overall survival (OS) in metastatic breast cancers \[[@CR11]--[@CR13]\]. In early breast cancers, it improves disease free survival (DFS) and OS \[[@CR14]--[@CR16]\] and increases pathological complete response (pCR) in a neoadjuvant setting when combined with chemotherapy (66.7% with trastuzumab versus 25% without) \[[@CR14],[@CR17],[@CR18]\].

Its antitumor activity is hypothesized to be related to two different mechanisms of action: downregulation of the intracellular signaling pathway *via* the PI3K and MAPK pathways, and activation of the immune response via antibody dependent cell-mediated cytotoxicity (ADCC) and eventually adaptive immune response \[[@CR19]--[@CR22]\].

Unfortunately, resistances to trastuzumab occur, mainly in the metastatic setting, where most of the patients treated with trastuzumab have a disease progression within one year \[[@CR23]\]. Molecular mechanisms of trastuzumab resistance may involve signaling from other HER receptors, such as HER3 or epidermal growth factor receptor (EGFR) \[[@CR24]\], insulin-like growth factor receptor \[[@CR25],[@CR26]\], activation of PI3K/AKT/mTOR \[[@CR27]\], overexpression of c-MET \[[@CR28]\] or loss of PTEN (phosphatase and TENsin homolog) \[[@CR27],[@CR29]\], up-regulation of src activity \[[@CR30]\] or MUC4 \[[@CR31],[@CR32]\], increased VEGF (vascular endothelial growth factor) expression \[[@CR33]\], expression of the p95 isoform of HER2 \[[@CR34]\] and co-expression of EGFR \[[@CR35]\].

In the present review, we will present clinical data on the main strategies that aimed at overcoming trastuzumab resistance. The targets and drug family under investigation are reported in Figure [1](#Fig1){ref-type="fig"}. The results of the main randomized trials are summarized in Table [1](#Tab1){ref-type="table"}.Figure 1**HER2-directed drugs and targets; mechanisms of action.**Table 1**Summary of randomized trials testing new drugs in Her2-overexpressing breast cancersDrugsTargetsStudyIdentifier numberPhaseSettingPrimary endpointTherapyResults**PertuzumabHER2/3CLEOPATRANCT00567190Phase IIIMBC/locally recurent/unresectablePFSTrastuzumab + docetaxel + pertuzumab18.7 monthsHR 0.69; 95% CI 0.58-0.81; *P* \<0.001in first linetrastuzumab + docetaxel + placebo12.4 monthsNEOSPHERENCT00545688Phase IINeo adjuvantpCRTrastuzumab + docetaxel29.0%Trastuzumab + pertuzumab + docetaxel45.8%*P* = 0.0141Pertuzumab + docetaxel24.0%Trastuzumab + pertuzumab16.8%T-DM1HER2EMILIANCT00829166Phase IIIMBCPFST-DM19.6 monthsHR 0.65; 95% CI 0.55-0.77; *P* \<0.001Lapatinib + Capecitabine6.4 monthsTH3RESANCT01419197Phase IIIMBC (in third line)T-DM16.2 monthsHR 0.528; 95% CI 0.422-0.661; *P* \<0.0001Physician's choice treatment3.3 monthsLapatinibHER1/HER2EGF104900NCT00320385Phase IIIMBC trastuzumab resistantPFSLapatinib + trastuzumab Lapatinib11.1 monthsHR 0.74; 95% CI 0.58-0.94; *P* = 0.0118.1 monthsNSABP B-41NCT00486668Phase IIINeo adjuvantpCRPaclitaxel + Trastuzumab53.5%Paclitaxel + Lapatinb52.5%Paclitaxel + Lapatinib + Trastuzumab62.0%NeoALTTONCT00553358Phase IIINeo adjuvantpCRPaclitaxel + Trastuzumab29.5%Paclitaxel + Lapatinb24.7%Paclitaxel + Lapatinib + Trastuzumab51.3%difference 21.1%; 95% CI 9.1-34.2; *P* = 0.0001).ALLTONCT00490139Phase IIIAdjuvantDFSTrastuzumab86.0%Trastuzumab + Lapatinib88.0%Sequential Trastuzumab/LapatinibGeyer and al.NCT00078572Phase IIILocally advanced/MBCTTPCapecitabine + Lapatinib Capecitabine8.4 monthsHR 0.57; 95% CI 0.44-0.77; *P* \<0.0014.4 monthGeparQuintoNCT00567554Phase IIINeo adjuvantpCRChemotherapy + Trastuzumab30.3%OR 0 · 68; 95% CI 0.47-0.97; *P* = 0 · 04Chemotherapy + Lapatinib22.7%BevacizumabVEGFAAVERELPhase IIILocally recurrent/MBCPFSDocetaxel + Trastuzumab + Bevacizumab Docetaxel + Trastuzumab16.8 months13.9 monthsBETHNCT00625898Phase IIIAdjuvantDFSChemotherapy + Trastuzumab + Bevacizumab Chemotherapy + TrastuzumabHR 1.00; 95% CI 0.79--1.26Everolimusm TORBOLERO-3NCT01007942Phase IIILocally advanced/MBCPFSTrastuzumab + Vinorelbine + Everolimus Trastuzumab + Vinorelbine30.4 weeksHR 0.78; 95% CI 0.65-0.96; *P* = 0.006725.1 weeksCI, confidence interval; DFS, disease free survival; HR, hazard ratio; MBC, metastatic breast cancer; mTOR, mammalian target of rapamycin; OR, odds ratio; pCR, pathological complete response; PFS, progression free survival; TTP, time to progression; VEGFA, vascular endothelial growth factor A.

Small tyrosine kinase inhibitors: Lapatinib and neratinib {#Sec2}
---------------------------------------------------------

### *Lapatinib* {#Sec3}

Lapatinib is a small molecule, dual tyrosine kinase inhibitor (TKI) of EGFR and HER2. It inhibits the intracellular kinase domain of HER2 contrary to trastuzumab that inhibits the extracellular domain and blocks ligand-induced heterodimer signaling. It could prevent signaling related to truncated HER2 receptor or enhance trastuzumab-dependant ADCC, thanks to an accumulation of HER2 at the cell surface.

It has shown its efficacy when combined with capecitabine, in terms of time to progression (hazard ratio (HR): 0.57; 95% confidence interval (CI) 0.43 to 0.77; *P* \<0.001). In the same trial, the median overall survival times were 75 weeks for the combination arm and 64.7 weeks for the capecitabine arm (HR 0.87; 95% CI 0.71 to 1.08; *P* = 0.210) \[[@CR36]--[@CR38]\]. Lapatinib has also shown its efficacy in terms of OS, when combined with paclitaxel, over paclitaxel single agent (HR 0.74; 95% CI 0.58 to 0.94; *P* = 0.0124) \[[@CR39]\].

The efficacy of dual HER2 blockade with trastuzumab and lapatinib was investigated in the phase III study EGF104900. Patients with HER2-positive metastatic breast cancer (MBC) who progressed during trastuzumab treatment were randomly assigned to receive lapatinib in monotherapy or lapatinib in combination with trastuzumab. The combination was associated with better outcome both in progression free survival (PFS) (HR 0.74; 95% CI 0.58 to 0.94; *P* = 0.011) and OS (HR 0.74; 95% CI 0.57 to 0.97; *P* = 0.026) \[[@CR40]\].

Following the results of these randomized trials in the metastatic setting, the efficacy of lapatinib has been investigated in early breast cancer, mainly in the context of trials testing dual inhibition of HER2. In the phase III trial of NSABP (protocol B-41), 529 patients were randomized to receive weekly paclitaxel with either trastuzumab weekly, lapatinib daily or the association trastuzumab plus lapatinib before undergoing surgery. Lapatinib alone had a similar percentage of pCR as trastuzumab (53.2% and 52.5%, respectively; *P* = 0.98). The dual HER2 blockade was associated with a higher pCR (62%; 95% CI 54.3 to 68.8) as compared to single-agent HER2 therapy but the difference was not statistically significant (*P* = 0.095) \[[@CR41]\].

In another randomized trial performed in the neo-adjuvant setting (Neo ALTTO), patients were randomized among lapatinib, trastuzumab or lapatinib plus trastuzumab, all in combination with paclitaxel after six weeks of targeted therapy alone. The pCR rate was significantly higher in the group treated with dual inhibition (51.3%) as compared to trastuzumab alone (29.5%) (a 21.1% difference; 95% CI 9.1 to 34.2; *P* = 0.0001). There was no significant difference in pCR between the lapatinib and the trastuzumab group \[[@CR42]\].

First results from the phase III ALLTO trial comparing one year of lapatinib alone, trastuzumab alone, their sequence or their combination in an adjuvant setting in 8,381 HER2 positive breast cancers have been reported \[[@CR42]\]. According to a predefined statistical plan, there was no statistically significant difference between dual targeting HER2 and trastuzumab (four years DFS: 88% versus 86%; HR 0.84; 97.5% CI 0.70 to 1.02; *P* = 0.048). Nevertheless, this lack of benefit could be related to the low number of events.

Neratinib {#Sec4}
---------

Neratinib is an oral irreversible pan-HER inhibitor. Preclinical data on breast cancer cell lines suggest that it could overcome both primary and acquired trastuzumab resistance in HER2 positive breast cancer cell lines \[[@CR43]\].

Neratinib has shown antitumor activity among both pretreated and trastuzumab naive patients. In a phase II trial, the median PFS observed with neratinib was 22.3 weeks among patients with prior trastuzumab treatment and 39.6 weeks with trastuzumab naive patients. Objective response rates were 24% and 56%, respectively \[[@CR44]\].

Neratinib single agent has been compared with the association of lapatinib plus capecitabine. Both median PFS (4.5 months) and OS (19.7 months) for neratinib single agent were found to be numerically inferior to that of the combination therapy, although not statistically significant (PFS 4.5 months versus 6.8 months; OS 19.7 months versus 23.6 months, *P* = 0.231 and *P* = 0.280, respectively) \[[@CR45]\].

Neratinib is currently developed in combination with paclitaxel, vinorelbine, capecitabine and temsirolimus \[[@CR46]--[@CR49]\]. The association of neratinib and capecitabine has been studied in a phase I/II trial. The median PFS was 40.3 weeks and the overall response rate was 57% for patients with no prior lapatinib treatment \[[@CR50]\]. An ongoing phase III study (NCT00915018) compares weekly paclitaxel with either neratinib or trastuzumab as first-line treatment for HER2-positive MBC.

The most common adverse event of this treatment is diarrhea in more than 90% of the cases, and then neutropenia (50% of the cases) \[[@CR46],[@CR48]\].

Vascular endothelial growth factor inhibitors {#Sec5}
---------------------------------------------

The vascular endothelial growth factor (VEGF) plays a key role in progression of this cancer by promoting tumor angiogenesis \[[@CR51]\]. Bevacizumab is a humanized monoclonal antibody which targets VEGF and inhibits VEGF signaling pathways.

In the AVEREL study, the efficacy of bevacizumab was evaluated in first line therapy for locally recurrent or metastatic HER2 positive breast cancer. In this phase III study, the HR for progression was 0.72 (95% CI 0.54 to 0.94; *P* = 0.0162). The median PFS was 16.8 months in the bevacizumab arm versus 13.9 months \[[@CR52]\].

Bevacizumab was also evaluated in HER2 positive, early breast cancer (BETH trial). In this trial, patients were randomly assigned to receive chemotherapy, trastuzumab plus bevacizumab, or chemotherapy and trastuzumab alone. No difference of efficacy was observed between the two arms (DFS, HR 1.00; 95% CI 0.79 to 1.26) \[[@CR53]\].

Other antiangiogenic agents that can target VEGFR, such as multitargeted anti-angiogenic TKIs (sunitinib, sorafenib, vandetanib) have shown promising results \[[@CR54]\].

Monoclonal antibodies: pertuzumab {#Sec6}
---------------------------------

Resistance to trastuzumab can be explained by signaling through other HER dimerization \[[@CR26]\]. Pertuzumab is an anti-HER2 antibody that inhibits HER2/HER3 dimerizations \[[@CR26],[@CR55]\] and, thus, can prevent these potential escape pathways. Binding of trastuzumab and pertuzumab is not mutually exclusive and their differing mechanisms of action act complementarily to provide a more complete blockade of HER2 signal transduction. The combination treatment with trastuzumab and pertuzumab has shown strongly enhanced antitumor activity in xenograft models with reduction in the levels of HER proteins \[[@CR56]\].

Cortes *et al*. have evaluated whether adding pertuzumab to trastuzumab could reverse trastuzumab resistance. The objective response rate and clinical benefit rate (CBR) were 3.4% and 10.3% in patients who received pertuzumab monotherapy after trastuzumab. At the opposite end, objective response rates and CBR were 17.6% and 41.2% in patients who received the combination after progression on trastuzumab \[[@CR57]\].

Based on these data, the efficacy of adding pertuzumab to trastuzumab has been investigated.

In the CLEOPATRA study, patients were randomized between placebo plus trastuzumab plus docetaxel or pertuzumab plus trastuzumab plus docetaxel. The median PFS was 12.4 months in the placebo group versus 18.7 months in the pertuzumab group (HR 0.69; 95% CI 0.58 to 0.81; *P* \<0.001). The pertuzumab arm was also associated with an OS improvement. The median OS in the placebo group was 37.6 months (95% CI 34.3 to NE (not estimable)) and had been not reached in the pertuzumab group (95% CI 42.4 to NE) (HR 0.66; 95% CI 0.52 to 0.84; *P* = 0.0008) \[[@CR58],[@CR59]\].

The combination of chemotherapy with trastuzumab and pertuzumab has also shown interesting results in the neo-adjuvant setting.

The NeoSphere study (multicenter phase II study) evaluated the efficacy of dual inhibition using pertuzumab. Patients who received pertuzumab and trastuzumab plus docetaxel had a significantly higher pCR rate (45.8%; 95% CI 36.1 to 55.7) compared to patients treated with trastuzumab and docetaxel (29%; 95% CI 20.6 to 38.5; *P* = 0.0141). Interestingly, pertuzumab and trastuzumab without chemotherapy was associated with a 16.8% pCR \[[@CR14]\].

TRYPHAENA is another comparative trial performed in the neoadjuvant setting. This trial investigated the efficacy of trastuzumab and pertuzumab with three cycles of FEC (5-fluorouracil, epirubicine, cyclophosphamide) then three cycles of docetaxel, or three FEC then three docetaxel with the combination of trastuzumab and pertuzumab or docetaxel plus carboplatin plus the combination during six cycles. The primary endpoint was to assess the cardiac safety. The pCR rates were quite similar in the three arms (61.6%, 57%, and 66.2%, respectively) \[[@CR60]\].

In the early stage of breast cancer, the efficacy of pertuzumab is currently being investigated in the adjuvant setting (APHINITY trial).

Antibody-drug conjugates: T-DM1 {#Sec7}
-------------------------------

Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate and is composed of trastuzumab covalently linked to maytansine, a cytotoxic agent \[[@CR61]\].

The EMILIA study, a phase III registration trial compared T-DM1 to lapatinib and capecitabine in patients with HER2 positive advanced breast cancer previously treated with trastuzumab and a taxane. The median PFS was 9.6 months with T-DM1 versus 6.4 months with lapatinib plus capecitabine (HR 0.65; 95% CI 0.55 to 0.77; *P* \<0.001). The median OS at the second interim analysis was 30.9 months in the T-DM1 arm versus 25.1 months in the lapatinib arm (HR 0.68; 95% CI 0.55 to 0.85; *P* \<0.001) \[[@CR62]\].

The phase III TH3RESA trial compared third line treatment (including trastuzumab and lapatinib) of metastatic or unresectable locally advanced or recurrent HER2 positive breast cancer with T-DM1 to the treatment of the physician's choice. T-DM1 treatment significantly improved PFS compared with physician's choice (median PFS 6.2 months versus 3.3 months; HR 0.528; 95% CI 0.422 to 0.661; *P* \<0.0001). Final overall survival analysis is still awaited but interim analysis showed a trend favoring T-DM1 with a lower incidence of grade 3 or worse adverse events \[[@CR63]\].

Another ongoing phase III trial, MARIANNE (NCT01120184), compares single-agent T-DM1 to T-DM1 combined with pertuzumab to trastuzumab plus a taxane in first line treatment of metastatic breast cancer.

These studies will provide more information about the indications of T-DM1 in the treatment algorithms for HER2-positive disease.

mTOR inhibitors/PI3K inhibitors {#Sec8}
-------------------------------

The mammalian target of rapamycin (mTOR) is a serine-threonine protein kinase that mediates mRNA translation and protein synthesis. Activation of this pathway is known as a mechanism of trastuzumab resistance \[[@CR29],[@CR64]\]. Preclinical studies have suggested that mTOR targeting could reverse resistance to trastuzumab \[[@CR65]\].

In a phase I/II study, patients with HER2-positive metastatic breast cancer received trastuzumab combined with everolimus, after resistance to trastuzumab. Fifteen percent of patients had a partial response and 19% had a long stable disease (≥6 months). The clinical benefit rate was 34% \[[@CR66]\].

A phase II study evaluated the efficacy of everolimus combined with trastuzumab and paclitaxel in patients who were resistant to trastuzumab and taxane therapy. The median PFS was 5.5 months and the median OS was 18.1 months \[[@CR67]\]. This combination is currently being evaluated in the BOLERO-1 trial.

The BOLERO-3 study compared the combination of everolimus, trastuzumab plus vinorelbine to trastuzumab and vinorelbine. The association of the mTOR inhibitor with vinorelbine significantly improved PFS (30.4 weeks in the everolimus arm versus 25.1 weeks in the placebo arm; HR 0.78; 95% CI 0.65 to 0.96; *P* = 0.0067). In this study, several biomarkers (PTEN, PIK3CA and pS6) were analyzed to find some subpopulation for whom the benefit of everolimus was higher. Patients with a low PTEN and high pS6 level seemed to derive more benefit from addition of everolimus. Median PFS gain was 12 weeks for the high pS6 level subgroup (HR 0.48; 95% CI 0.24 to 0.96) and 18 weeks for the low PTEN subgroup (HR 0.41; 95% CI 0.20 to 0.82). Unfortunately, there was no marker-treatment interaction with PIK3CA mutation. These promising results deserve additional research.

Building on these results, the combination between trastuzumab and BKM120, an oral pan-class 1 PI3K inhibitor, has been developed. It inhibits this signaling pathway thanks to an ATP-competitive action. Several objective responses were observed in a phase I study \[[@CR68]\], and this combination is currently being investigated in a randomized trial in the neoadjuvant setting (neoPHOEBE trial).

HSP90 inhibitors {#Sec9}
----------------

Heat shock protein 90 (HSP90) is a chaperone which stabilizes oncogenic proteins. Inhibition of HSP90 leads to the degradation of these proteins involved in cancer biology \[[@CR69]\]. HSP90 inhibitors are currently being developed in ALK-translocated lung cancer, myeloma and gastrointestinal stromal tumor (GIST). In HER2 positive breast cancer, HSP90 inhibitors have shown antitumor activity when combined with trastuzumab \[[@CR70]\].

17-Demethoxygeldanamycin (17-AAG) inhibits the activity of HSP90, thereby inducing the degradation of many oncogenic proteins. In a phase II study, 17-AAG (tanespimycin) was given in combination with trastuzumab in patients who previously failed to trastuzumab. The overall response rate (ORR) was 22%, the CBR was 59%, the median PFS was six months and the median OS was seventeen months \[[@CR71]\].

In another phase II study, retaspimycin (IPI-504) given with trastuzumab showed modest clinical activity, but it is possible that under-dosing limited efficacy \[[@CR72]\]. Other studies employing higher doses are ongoing.

These findings are promising and other studies are expected to develop these new targeted therapies.

Blockade of PD-1/PD-L1 immune checkpoint {#Sec10}
----------------------------------------

Programmed death 1 (PD-1) is a co-inhibitory receptor and acts as a negative regulator of the immune system. It is overexpressed on tumor-infiltrating lymphocytes (TIL). The PD-1 ligand, PD-L1, is expressed by multiple carcinoma, including breast cancers. This suggests that the PD-1/PD-L1 signaling pathway could be a candidate target in breast and other cancers.

T cell infiltration is predictive for the efficacy of trastuzumab \[[@CR73]--[@CR76]\]. Biomarker studies have shown that PD-1+ TILs are associated with poor prognosis in HER2 positive breast cancer \[[@CR77],[@CR78]\] and preliminary data also suggest a relationship between PD-L1 expression on tumor cells and objective response to anti PD-1 therapy \[[@CR79]\]. The effects of anti-PD-1 and anti-PD-L1 antibodies have been investigated in phase I trials in various cancer types and have shown encouraging responses (response rate 6 to 28% and stabilized disease rate 12% to 41%) \[[@CR80],[@CR81]\].

Preclinical studies have shown a synergism between trastuzumab and anti-PD1 antibodies \[[@CR82]\].

Other monoclonal antibody (mAb)-based therapies are being investigated including anti CD73. Pre-clinical data have suggested that it can delay tumor growth and inhibit the development of metastases \[[@CR83]\].

Conclusions {#Sec11}
===========

Although trastuzumab remains the standard treatment in patients with HER2 overexpressing breast cancer in neoadjuvant, adjuvant and metastatic settings, the presence of acquired and *de novo* resistance is a serious concern. The understanding of resistance mechanisms could allow developing strategies to prevent or overcome this resistance. The development of novel targeted therapies has changed the practices in metastatic settings.

New standards of care include trastuzumab plus pertuzumab plus docetaxel in first line treatment and TDM-1 for trastuzumab-resistant patients. In early breast cancer, dual HER2 blockade has shown promising results in the neoadjuvant setting. This strategy is being evaluated in the adjuvant setting in several randomized trials.

Since several different targets are under investigation, there is a need to identify predictive biomarkers to optimize combination strategies for suitable patients. Loss of PTEN and a high level of pS6 could facilitate the selection of appropriate patients who can benefit from personalized targeted therapy.
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